Loading stock data…
MIRA
$0.98-0.02 (-2.33%)
After Hours$0.98+0.00 (+0.00%)· Last close Jun 9
MIRA Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MIRA Pharmaceuticals, Inc. in the Healthcare sector is trading at $0.98. The stock is currently near its 52-week low of $0.90, remaining 24.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.98
Potential Downside
0%
Whystock Fair Value$0.98
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican righ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-104.92%
Volume
Today's trading volume
103,634
Recent News
Tapestry patents AI data analytics tech
The Coach owner said it is trimming the time it takes to analyze data through its newly patented AI technology.
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Aurora Cannabis Announced Refocused Strategy as Global Medical Sales Hit Record High in 2026 Third Quarter Canopy Growth Reported Mixed Results in its Fiscal Third Quarter of 2026 Cronos Group Launched Premium Lord Jones Brand in Israel in Global Expansion Push Key Takeaways; Psychedelic Sector Clearmind Announced the Inclusion of its […]
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks fell late Thursday afternoon with the NYSE Health Care Index down 0.2% and the He
Top Premarket Gainers
FiEE (MINM) shares were up 37% in recent Thursday premarket activity, after the company said Wednesd
EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) on Monday revealed new animal study results from SKNY-1, a next-generation oral therapeutic. The company says the findings further support the advancement of SKNY-1 toward Investigational New Drug (IND) enabling studies. With obesity and smoking representing two of the leading causes of preventable death and a combined global market opportunity exceeding $200 billion, MIRA intends to prioritize SKNY-1 as a potential cornerstone asset pending the completio